On Monday, Adc Therapeutics SA (NYSE: ADCT) was 6.35% up from the session before settling in for the closing price of $3.15. A 52-week range for ADCT has been $1.05 – $4.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 1.38% over the last five years. When this article was written, the company’s average yearly earnings per share was at 8.89%. With a float of $77.65 million, this company’s outstanding shares have now reached $99.18 million.
The firm has a total of 265 workers. Let’s measure their productivity. In terms of profitability, gross margin is 90.97%, operating margin of -178.81%, and the pretax margin is -212.48%.
Adc Therapeutics SA (ADCT) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Adc Therapeutics SA stocks. The insider ownership of Adc Therapeutics SA is 21.71%, while institutional ownership is 74.76%. The most recent insider transaction that took place on Dec 11 ’24, was worth 304,500. In this transaction 10% Owner of this company bought 100,000 shares at a rate of $3.04, taking the stock ownership to the 15,666,731 shares. Before that another transaction happened on Dec 11 ’24, when Company’s 10% Owner bought 100,000 for $3.04, making the entire transaction worth $304,500. This insider now owns 13,145,712 shares in total.
Adc Therapeutics SA (ADCT) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 8.89% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.36% during the next five years compared to 1.38% growth over the previous five years of trading.
Adc Therapeutics SA (NYSE: ADCT) Trading Performance Indicators
You can see what Adc Therapeutics SA (ADCT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.16. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.45, a number that is poised to hit -0.39 in the next quarter and is forecasted to reach -1.31 in one year’s time.
Technical Analysis of Adc Therapeutics SA (ADCT)
Analysing the last 5-days average volume posted by the [Adc Therapeutics SA, ADCT], we can find that recorded value of 0.7 million was better than the volume posted last year of 0.57 million. As of the previous 9 days, the stock’s Stochastic %D was 91.94%.
During the past 100 days, Adc Therapeutics SA’s (ADCT) raw stochastic average was set at 78.77%, which indicates a significant decrease from 95.81% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.22 in the past 14 days, which was higher than the 0.19 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.62, while its 200-day Moving Average is $2.21. Now, the first resistance to watch is $3.48. This is followed by the second major resistance level at $3.62. The third major resistance level sits at $3.85. If the price goes on to break the first support level at $3.12, it is likely to go to the next support level at $2.89. Should the price break the second support level, the third support level stands at $2.75.
Adc Therapeutics SA (NYSE: ADCT) Key Stats
There are 99,178K outstanding shares of the company, which has a market capitalization of 332.25 million. As of now, sales total 70,840 K while income totals -157,850 K. Its latest quarter income was 23,030 K while its last quarter net income were -38,600 K.
